Clinical trial
GPX-100 in Treating Patients With Solid Tumors
NCT00003403 · Gem Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00003403 |
|---|---|
| Title | GPX-100 in Treating Patients With Solid Tumors |
| Official title | Phase I Safety and Efficacy Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer |
| Lead sponsor | Gem Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | GPX-100 |
| Start date | Aug 1, 1999 |
| First posted | May 24, 2004 |
| Last update posted | Apr 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: